Janssen Pharmaceuticals Inc.
www.janssenpharmaceuticalsinc.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Janssen Pharmaceuticals Inc.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Biosimilar Substitution In Medicare Part D Formularies Mid-Year Established In Final Rule
Policy may be helpful in promoting acceptance of follow-ons in Medicare but is not expected to result in near-term savings to the program.
Biosimilar Substitution In Medicare Part D Formularies Mid-Year Established In Final Rule
Policy may be helpful in promoting acceptance of follow-ons in Medicare but is not expected to result in near-term savings to the program.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice